期刊文献+

达比加群酯对1例肺栓塞患者凝血功能的影响 被引量:4

Effect of Dabigatran Etexilate on Blood Coagulation Indexes in a Patient with Pulmonary Embolism
原文传递
导出
摘要 目的探讨达比加群酯对凝血功能的影响及抗凝活性监测的意义。方法临床药师根据1例肺栓塞患者服用达比加群酯的凝血指标,提出合理的药物治疗建议。结果患者部分凝血活酶时间(activated partial thromboplastin time,APTT)延长超过正常上限(upper limit of normal,ULN)2倍,临床药师建议服药后12 h重新检验APTT,目标值为1.5倍ULN,患者复查后达标。结论特殊人群常规凝血指标监测有助于明确抗凝疗效,采血时机非常关键。APTT可供定性评估,但结果解读需谨慎。 OBJECTIVE To discuss the influence of dabigatran etexilate on coagulation function and the significance of anticoagulant activity monitoring. METHODS The clinical pharmacist put forward some reasonable drug treatment suggestions according to the coagulation indexes of dabigatran etexilate in a patient with pulmonary embolism. RESULTS The patient with activated partial thromboplastin time(APTT) prolonged more than 2 times of the upper limit of normal(ULN), and clinical pharmacist suggested the APTT should be re-examined 12 h after the last dose and target value was 1.5 times of ULN, and the target was met after the re-examination. CONCLUSION Routine coagulation tests can help determine anticoagulant effect in specific populations and the timing of blood sampling is very critical. The APTT may provide a qualitative assessment but the results need to carefully interpretate.
作者 章晔 陈晔 ZHANG Ye;CHEN Ye(The Second Affiliated Hospital of Zhejiang Chinese Medical University,1.Department of Pharmacy;Department of Respiratory,Hangzhou 310005,China)
出处 《中国现代应用药学》 CAS CSCD 北大核心 2018年第9期1405-1407,共3页 Chinese Journal of Modern Applied Pharmacy
关键词 达比加群酯 肺栓塞 凝血功能 临床药师 dabigatran etexilate pulmonary embolism coagulation assays clinical pharmacist
  • 相关文献

参考文献2

二级参考文献77

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1401
  • 2胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 3邹治鹏,何建国,程显声,赵彦芬,陈白屏,高莹,熊长明,倪新海,荆志诚.230例急性肺动脉血栓栓塞症患者对症治疗、抗凝治疗和溶栓治疗的住院转归[J].中国循环杂志,2006,21(3):219-221. 被引量:27
  • 4WolfeTR, AllenTL. Syncope as an emergency department presentation of pulmonary embolism[J]. J Emerg Med, 16(1):27–31.
  • 5KonstantinidesSV. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism[J]. Eur Heart J, 2014, 35(45): 3145–3146. DOI:10.1093/eurheartj/ehu393.
  • 6HeitJA. The epidemiology of venous thromboembolism in the community[J]. Arterioscler Thromb Vasc Biol, 2008,28(3):370–372.DOI: 10.1161/ATVBAHA.108.162545.
  • 7CohenAT, AgnelliG, AndersonFA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality[J]. Thromb Haemost, 2007,98(4):756–764.
  • 8YangY, LiangL, ZhaiZ, et al. Pulmonary embolism incidence and fatality trends in chinese hospitals from 1997 to 2008: a multicenter registration study[J]. PLoS One, 2011,6(11):e26861.DOI: 10.1371/journal.pone.0026861.
  • 9LaporteS, MismettiP, DécoususH, et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry[J]. Circulation, 2008,117(13):1711–1716.DOI: 10.1161/CIRCULATIONAHA.107.726232.
  • 10GoldhaberSZ, VisaniL, De RosaM. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)[J]. Lancet, 1999,353(9162):1386–1389.

共引文献693

同被引文献35

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部